Pharmacological doses of nicotinic acid induce a profound change in the plasma levels of various lipids and lipoproteins. The ability of nicotinic acid to strongly increase the plasma concentration of high-density lipoprotein (HDL) cholesterol has in recent years led to an increased interest in the pharmacological potential of nicotinic acid. There is increasing evidence that nicotinic acid alone or in addition to LDL cholesterol-lowering drugs can reduce the progression of atherosclerosis and reduce the risk of cardiovascular events. The clinical use of nicotinic acid is, however, hindered by harmless but unpleasant side effects, especially by a strong cutaneous vasodilation called flushing. The recent discovery of the G protein-coupled receptor GPR109A (HM74A or PUMA-G) as a receptor for nicotinic acid has allowed for better understanding of the mechanisms underlying the metabolic and vascular effects of nicotinic acid. On the basis of recent progress in understanding the pharmacological effects of nicotinic acid, new strategies are in development to better exploit the pharmacological potential of nicotinic acid. New drugs acting via the nicotinic acid receptor or related receptors, as well as new co-medications that suppress unwanted effects of nicotinic acid, will most likely be introduced as new therapeutic options in the treatment of dyslipidemia and the prevention of cardiovascular diseases.

Heterotrimeric G proteins are molecular switches that regulate numerous signaling pathways involved in cellular physiology. This characteristic is achieved by the adoption of two principal states: an inactive, GDP bound state and an active, GTP bound state. Under basal conditions, G proteins exist in the inactive, GDP bound state; thus, nucleotide exchange is crucial to the onset of signaling. Despite our understanding of G protein signaling pathways, the mechanism of nucleotide exchange remains elusive. We employed phage display technology to identify nucleotide state-dependent Galpha binding peptides. Herein, we report a GDP-selective Galpha binding peptide, KB-752, that enhances spontaneous nucleotide exchange of Galpha(i) subunits. Structural determination of the Galpha(i1)/peptide complex reveals unique changes in the Galpha switch regions predicted to enhance nucleotide exchange by creating a GDP dissociation route. Our results cast light onto a potential mechanism by which Galpha subunits adopt a conformation suitable for nucleotide exchange.

Regulator of G-protein signaling (RGS) proteins areGTPase activating proteins (GAPs) of heterotrimeric Gproteins that alter the amplitude and kinetics of receptor-promoted signaling. In this study we defined the G-protein ␣-subunit selectivity of purified Sf9 cell-derived R7 proteins, a subfamily of RGS proteins (RGS6, -7, -9, and -11) containing a G␥-like (GGL) domain that mediates dimeric interaction with G␤ 5 . G␤ 5 /R7 dimers stimulated steady state GTPase activity of G␣-subunits of the G i family, but not of G␣ q or G␣ 11 , when added to proteoliposomes containing M2 or M1 muscarinic receptor-coupled G-protein heterotrimers. Concentration effect curves of the G␤ 5 /R7 proteins revealed differences in potencies and efficacies toward G␣-subunits of the G i family. Although all four G␤ 5 /R7 proteins exhibited similar potencies toward G␣ o , G␤ 5 /RGS9 and G␤ 5 /RGS11 were more potent GAPs of G␣ i1 , G␣ i2 , and G␣ i3 than were G␤ 5 /RGS6 and G␤ 5 /RGS7. The maximal GAP activity exhibited by G␤ 5 /RGS11 was 2-to 4-fold higher than that of G␤ 5 /RGS7 and G␤ 5 /RGS9, with G␤ 5 /RGS6 exhibiting an intermediate maximal GAP activity. Moreover, the less efficacious G␤ 5 /RGS7 and G␤ 5 /RGS9 inhibited G␤ 5 / RGS11-stimulated GTPase activity of G␣ o . Therefore, R7 family RGS proteins are G i family-selective GAPs with potentially important differences in activities.Heterotrimeric guanine nucleotide-binding proteins (G-proteins) act as molecular switches in multiple GPCR 1 signaling pathways via regulation of specific effector molecules such as phospholipase C and adenylyl cyclase. The biological activity of G-protein ␣-subunits is determined by the identity of the bound guanine nucleotide (GTP or GDP), which in turn is governed by the relative rates of guanine nucleotide exchange and hydrolysis of GTP by the intrinsic GTPase activity of G␣-subunits.These opposing reactions are stimulated by agonist-occupied GPCR and GTPase-activating proteins (GAPs).Although some effector proteins exhibit GAP activity (1-3), the primary regulators of GTPase activity of G␣-subunits are a diverse family of regulator of G-protein signaling (RGS) proteins that act as GAPs for heterotrimeric G-protein ␣-subunits (4 -7). This family is defined by a conserved RGS domain, which markedly increases the rate of GTP hydrolysis by G␣-subunits and terminates effector activation by both G␣-and G␤␥-subunits. More than 30 RGS proteins have been identified and organized into subfamilies based on sequence similarity and domain structure. These families vary in size and complexity, from the R4 family whose structure is largely limited to the RGS domain to the R12 and RhoGEF families whose members are large multifunctional proteins containing several domains (for reviews see Refs. 8 -10).The R7 RGS family is a unique multidomain family, which consists of RGS proteins containing a novel G-␥-like (GGL) domain homologous to the G␥-subunit of heterotrimeric Gproteins (11). This domain, found in the mammalian proteins RGS6, -7, -9, and -11 and the Caenorhabdi...

Nicotinic acid has been used for decades to treat dyslipidaemic states. In particular its ability to raise the plasma HDL cholesterol concentration has led to an increased interest in its pharmacological potential. The clinical use of nicotinic acid is somewhat limited due to several harmless but unpleasant side effects, most notably a cutaneous flushing phenomenon. With the recent discovery of a nicotinic acid receptor, it has become possible to better understand the mechanisms underlying the metabolic and vascular effects of nicotinic acid. Based on these new insights into the action of nicotinic acid, novel strategies are currently under development to maximize the pharmacological potential of this drug. The generation of both flushreducing co-medications of nicotinic acid and novel drugs targeting the nicotinic acid receptor will provide future therapeutic options for the treatment of dyslipidaemic disorders.

The human P2Y 12 receptor (P2Y 12 -R) is a member of the G protein coupled P2Y receptor family, which is intimately involved in platelet physiology. We describe here the purification and functional characterization of recombinant P2Y 12 -R after high-level expression from a baculovirus in Sf9 insect cells. Purified P2Y 12 -R, G␤ 1 ␥ 2 , and various G␣-subunits were reconstituted in lipid vesicles, and steady-state GTPase activity was quantified. GTP hydrolysis in proteoliposomes formed with purified P2Y 12 -R and G␣ i2 ␤ 1 ␥ 2 was stimulated by addition of either 2-methylthio-ADP (2MeSADP) or RGS4 and was markedly enhanced by their combined presence. 2MeSADP was the most potent agonist (EC 50 ϭ 80 nM) examined, whereas ADP, the cognate agonist of the P2Y 12 -R, was 3 orders of magnitude less potent. ATP had no effect alone but inhibited the action of 2MeSADP; therefore, ATP is a relatively low-affinity antagonist of the P2Y 12 -R. The G protein selectivity of the P2Y 12 -R was examined by reconstitution with various G protein ␣-subunits in heterotrimeric form with G␤ 1 ␥ 2 . The most robust coupling of the P2Y 12 -R was to G␣ i2 , but effective coupling also occurred to G␣ i1 and G␣ i3 . In contrast, little or no coupling occurred to G␣ o or G␣ q . These results illustrate that the signaling properties of the P2Y 12 -R can be studied as a purified protein under conditions that circumvent the complications that occur in vivo because of nucleotide metabolism and interconversion as well as nucleotide release.